Brandywine Global Investment Management LLC Acquires 97,633 Shares of Genmab A/S Sponsored ADR $GMAB

Key Points

• Brandywine Global Investment Management LLC increased its stake in Genmab A/S by 6.0%, owning approximately $33.63 million in stock, following the acquisition of an additional 97,633 shares.
• Several large investors, including Deep Track Capital and Two Sigma Advisors, have also significantly increased their positions in Genmab A/S during the fourth quarter, indicating growing institutional interest.
• Equities analysts have a consensus rating of "Moderate Buy" for Genmab A/S, with target prices ranging between $36.00 and $46.00, underscoring positive sentiment toward the company's growth potential.

Brandywine Global Investment Management LLC raised its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 6.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,717,397 shares of the company's stock after purchasing an additional 97,633 shares during the quarter. Brandywine Global Investment Management LLC owned about 0.27% of Genmab A/S worth $33,627,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. Headlands Technologies LLC lifted its holdings in Genmab A/S by 1,525.0% in the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock worth $31,000 after buying an additional 1,464 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its position in shares of Genmab A/S by 124.3% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock worth $38,000 after buying an additional 1,070 shares in the last quarter. Barclays PLC raised its holdings in Genmab A/S by 1,072.8% in the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after acquiring an additional 2,285 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Genmab A/S in the fourth quarter valued at $60,000. Finally, Advisors Preferred LLC bought a new position in Genmab A/S during the 1st quarter valued at $84,000. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Price Performance

Shares of GMAB traded up $0.3350 during trading hours on Thursday, hitting $24.3950. 1,076,557 shares of the company were exchanged, compared to its average volume of 1,434,208. The firm has a fifty day simple moving average of $21.87 and a 200-day simple moving average of $21.00. The company has a market capitalization of $15.65 billion, a PE ratio of 12.25, a PEG ratio of 6.91 and a beta of 0.95. Genmab A/S Sponsored ADR has a one year low of $17.24 and a one year high of $27.94.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The business had revenue of $925.00 million for the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. Sell-side analysts expect that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Zacks Research downgraded Genmab A/S from a "strong-buy" rating to a "hold" rating in a report on Tuesday. Wall Street Zen upgraded Genmab A/S from a "hold" rating to a "buy" rating in a research note on Monday, July 28th. HC Wainwright boosted their target price on shares of Genmab A/S from $35.00 to $36.00 and gave the company a "buy" rating in a research note on Friday, August 15th. Finally, Truist Financial raised their price target on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research report on Tuesday, July 8th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Genmab A/S has an average rating of "Moderate Buy" and an average price target of $37.60.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.